---
title: "Indivior Pharmaceuticals, Inc. (INDV.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/INDV.US.md"
symbol: "INDV.US"
name: "Indivior Pharmaceuticals, Inc."
industry: "制药"
---

# Indivior Pharmaceuticals, Inc. (INDV.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 美股市场 |
| Website | [www.indivior.com](https://www.indivior.com) |

## Company Profile

Indivior Pharmaceuticals, Inc.及其子公司开发、生产和销售基于布洛芬的处方药，旨在治疗美国、欧洲、加拿大、澳大利亚及国际市场的阿片类药物依赖及相关疾病。该公司开发用于治疗物质使用障碍的药物。其核心市场产品包括 SUBLOCADE 布洛芬缓释月注射剂；SUBOXONE 薄膜，一种布洛芬和纳洛酮的舌下薄膜；SUBOXONE 片，一种布洛芬和纳洛酮的舌下片；以及 SUBUTEX 片，一种用于治疗阿片类药物使用障碍（OUD）的布洛芬舌下片。该公司还提供 OPVEE 鼻用喷雾剂，用于阿片类药物过量的逆转

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:15.000Z

**Overall: C (0.56)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 54 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.17% |  |
| Net Profit YoY | 236.26% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -20.44 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.23B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.18B |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -66.31% | E |
| Profit Margin | 10.51% | B |
| Gross Margin | 85.35% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.17% | D |
| Net Profit YoY | 236.26% | A |
| Total Assets YoY | -3.28% | D |
| Net Assets YoY | -23.95% | E |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 951.61% | B |
| OCF YoY | -0.17% | D |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.82 | B |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 114.62% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Indivior Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-66.31%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "10.51%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "85.35%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.17%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "236.26%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.28%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-23.95%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "951.61%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-0.17%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.82",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "114.62%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 礼来 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 罗氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 诺华制药 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 34.12 | 46/257 | 56.85 | 52.10 | 34.84 |
| PB | -20.44 | 222/257 | - | - | - |
| PS (TTM) | 3.59 | 83/257 | 3.55 | 2.44 | 1.20 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-27T05:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 5 | 71% |
| Overweight | 2 | 29% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 33.89 |
| Highest Target | 50.00 |
| Lowest Target | 36.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/INDV.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/INDV.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/INDV.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.